Site Search

The following is a collection of information and news about Trikafta^®, the triple-combination modulator therapy.

Trikafta^®, a highly effective modulator therapy initially approved by the FDA on October 21, 2019, treats the underlying cause of CF. The following are commonly asked questions about Trikafta.

Drugs that target the underlying defect in the cystic fibrosis transmembrane conductance regulator (CFTR) protein are called CFTR modulators. The two main types of modulators are potentiators and correctors.

Theratyping matches therapies, or medications, to specific types of mutations. The primary goal of theratyping is to identify which mutations respond to certain CFTR modulators, thereby helping people with rare CFTR mutations gain access to already approved modulators quickly and safely.